Evidence map›Paper›PMID 35285676›Full record

ArticleAntimicrobial agents and chemotherapy2022

Monoclonal Antibodies Targeting Surface-Exposed Epitopes of Candida albicans Cell Wall Proteins Confer

Soumya Palliyil, Mark Mawer, Sami A Alawfi, Lily Fogg, Tyng H Tan, Giuseppe Buda De Cesare, Louise A Walker, Donna M MacCallum, Andrew J Porter, Carol A Munro

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. A Synthetic β-Mannan Epitope Enables Immunization and Detection of Candida auris.Angewandte Chemie (International ed. in English) · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Architecture of the dynamic fungal cell wall.Nature reviews. Microbiology · 2023
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Soumya PalliyilScottish Biologics Facility, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeengrid.7107.1, Aberdeen, United Kingdom.ORCID 0000-0002-6203-8106
Mark MawerScottish Biologics Facility, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeengrid.7107.1, Aberdeen, United Kingdom.
Sami A AlawfiAberdeen Fungal Group, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeengrid.7107.1, Aberdeen, United Kingdom.
Lily FoggScottish Biologics Facility, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeengrid.7107.1, Aberdeen, United Kingdom.
Tyng H TanScottish Biologics Facility, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeengrid.7107.1, Aberdeen, United Kingdom.
Giuseppe Buda De CesareAberdeen Fungal Group, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeengrid.7107.1, Aberdeen, United Kingdom.
Louise A WalkerAberdeen Fungal Group, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeengrid.7107.1, Aberdeen, United Kingdom.ORCID 0000-0002-2236-8776
Donna M MacCallumAberdeen Fungal Group, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeengrid.7107.1, Aberdeen, United Kingdom.
Andrew J PorterScottish Biologics Facility, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeengrid.7107.1, Aberdeen, United Kingdom.
Carol A MunroAberdeen Fungal Group, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeengrid.7107.1, Aberdeen, United Kingdom.
University of Aberdeen · GB

Funding

Medical Research Council MR/P501955/1
6 · The paper itself

Abstract

Monoclonal antibody (mAb)-based immunotherapies targeting systemic and deep-seated fungal infections are still in their early stages of development, with no licensed antifungal mAbs currently being available for patients at risk. The cell wall glycoproteins of Candida albicans are of particular interest as potential targets for therapeutic antibody generation due to their extracellular location and key involvement in fungal pathogenesis. Here, we describe the generation of recombinant human antibodies specifically targeting two key cell wall proteins (CWPs) in C. albicans: Utr2 and Pga31. These antibodies were isolated from a phage display antibody library using peptide antigens representing the surface-exposed regions of CWPs expressed at elevated levels during

Indexed as

Antibodies, MonoclonalCandida albicansAnimalsAntibodies, FungalAntifungal AgentsAntigens, FungalCaspofunginCell WallEpitopesHumansMiceAntibodies, FungalAntibodies, MonoclonalAntifungal AgentsAntigens, FungalCaspofunginEpitopesanti-Candida mAbsCandida albicansimmunotherapymonoclonal antibodies

Identifiers

PMID35285676
PMCPMC9017365
OpenAlexW4221015194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.